Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

• Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial

  2025 British Journal of Cancer article Medicine Gastrointestinal Tumor Research and Treatment Open access

  4

  citations
• Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

  2024 Nature Medicine article Medicine Gastrointestinal Tumor Research and Treatment Open access

  62

  citations
• Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study

  2023 European Journal of Cancer article Medicine Gastrointestinal Tumor Research and Treatment Open access

  11

  citations
• Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data

  2023 Targeted Oncology article Medicine Gastrointestinal Tumor Research and Treatment Open access

  16

  citations
• Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

  2022 BMC Cancer article Medicine Gastrointestinal Tumor Research and Treatment Open access

  10

  citations
• Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients

  2022 Targeted Oncology article Medicine Gastrointestinal Tumor Research and Treatment Open access

  5

  citations
• Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

  2022 Journal of Clinical Oncology article Medicine Gastrointestinal Tumor Research and Treatment Open access

  121

  citations
• Automated gathering of real-world data from online patient forums can complement pharmacovigilance for rare cancers

  2022 Scientific Reports article Pharmacology, Toxicology and Pharmaceutics Pharmacovigilance and Adverse Drug Reactions Open access cited by 1 patent

  10

  citations
• A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor

  2022 BMC Cancer article Medicine Gastrointestinal Tumor Research and Treatment Open access

  11

  citations
• SELNET clinical practice guidelines for soft tissue sarcoma and GIST

  2021 Cancer Treatment Reviews article Medicine Sarcoma Diagnosis and Treatment Open access

  76

  citations
• Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

  2021 Annals of Oncology article Medicine Gastrointestinal Tumor Research and Treatment Open access

  603

  citations
• Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study

  2021 The Oncologist article Medicine Gastrointestinal Tumor Research and Treatment Open access

  34

  citations
• Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice

  2021 Gastric Cancer article Medicine Gastrointestinal Tumor Research and Treatment Open access

  8

  citations
• Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆

  2021 Annals of Oncology article Medicine Gastrointestinal Tumor Research and Treatment Open access

  75

  citations
• Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib

  2020 Expert Opinion on Investigational Drugs article Medicine Gastrointestinal Tumor Research and Treatment Open access

  31

  citations
• Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

  2020 The Lancet Oncology article Medicine Gastrointestinal Tumor Research and Treatment Open access cited by 48 patents

  430

  citations
• Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’

  2020 European Journal of Cancer article Medicine Gastrointestinal Tumor Research and Treatment

  72

  citations
• Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study

  2020 British Journal of Cancer article Medicine Gastrointestinal Tumor Research and Treatment Open access

  24

  citations

18 results